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Although inhibition of cyclic nucleotide phosphodiesterase type 3
(PDE3) has been reported to protect rodent heart against ischemia/
reperfusion (I/R) injury, neither the specific PDE3 isoform involved
nor the underlying mechanisms have been identified. Targeted
disruption of PDE3 subfamily B (PDE3B), but not of PDE3 sub-
family A (PDE3A), protected mouse heart from I/R injury in vivo
and in vitro, with reduced infarct size and improved cardiac
function. The cardioprotective effect in PDE3B−/− heart was re-
versed by blocking cAMP-dependent PKA and by paxilline, an in-
hibitor of mitochondrial calcium-activated K channels, the opening
of which is potentiated by cAMP/PKA signaling. Compared with WT
mitochondria, PDE3B−/− mitochondria were enriched in antiapop-
totic Bcl-2, produced less reactive oxygen species, and more fre-
quently contacted transverse tubules where PDE3B was localized
with caveolin-3. Moreover, a PDE3B−/− mitochondrial fraction con-
taining connexin-43 and caveolin-3 was more resistant to Ca2+-
induced opening of the mitochondrial permeability transition pore.
Proteomics analyses indicated that PDE3B−/− heart mitochondria
fractions were enriched in buoyant ischemia-induced caveolin-3–
enriched fractions (ICEFs) containing cardioprotective proteins. Ac-
cumulation of proteins into ICEFs was PKA dependent and was
achieved by ischemic preconditioning or treatment of WT heart
with the PDE3 inhibitor cilostamide. Taken together, these find-
ings indicate that PDE3B deletion confers cardioprotective effects
because of cAMP/PKA-induced preconditioning, which is associated
with the accumulation of proteins with cardioprotective function in
ICEFs. To our knowledge, our study is the first to define a role for
PDE3B in cardioprotection against I/R injury and suggests PDE3B as a
target for cardiovascular therapies.
PDE3B−/− mice | protein kinase A | ischemia/reperfusion injury |
signalosome | membrane repair
The two cyclic nucleotide phosphodiesterase type 3 (PDE3)subfamilies PDE3A and PDE3B are products of separate but
homologous genes. PDE3 isoforms hydrolyze both cAMP and cGMP
with high affinity (Km <1 μM) in a mutually competitive manner and
are important regulators of cyclic nucleotide signaling pathways
and responses in cardiomyocytes and vascular smooth muscle (1).
PDE3A and PDE3B exhibit different patterns of expression. PDE3A
is more abundant in platelets, airway and vascular smooth muscle,
and cardiovascular tissues, whereas PDE3B is relatively more highly
expressed in tissues that are important in regulating energy metab-
olism, including liver, pancreatic β cells, brown adipose tissue (BAT),
and white adipose tissue (WAT) (2). Little is known about their
differential localization and functions when PDE3A and PDE3B are
present in the same cell. To gain further insight into specific PDE3A
and PDE3B functions in physiological contexts, we have generated
and studied PDE3A−/− and PDE3B−/− mice (3, 4).
PDE3 inhibitors, e.g., milrinone, are thought to enhance
myocardial inotropic responses via cAMP/PKA regulation of
Ca2+ cycling in the sarcoplasmic reticulum (SR) (1, 5). The
PDE3 inhibitor cilostazol (6–9) and the PDE5 inhibitor sildenafil
(10, 11) have been reported to protect hearts against ischemia/
reperfusion (I/R) injury in various species. Fukasawa et al. (8)
have suggested that cilostazol exerts its cardioprotective effect by
activating mitochondrial Ca2+-activated K+ (mitoKCa) channels,
whose opening protects hearts against infarction (12). Further-
more, studies have shown that the opening of mitoKCa channels
is potentiated by cAMP-dependent PKA signaling (13), whereas
PKC potentiates mitochondrial ATP-sensitive K+ (mitoKATP)
channel activation (14). Kukreja and his associates have sug-
gested that the cardioprotective effects of sildenafil are mediated
by activation of both mitoKATP (10) and mitoKCa channels (11).
Ischemic preconditioning (PreC), a process in which brief in-
termittent episodes of ischemia and reperfusion protect the heart
from subsequent prolonged ischemic injury (15), initiates a number
of cardioprotective signaling pathways at the plasma membrane,
which are transduced to mitochondria (16). According to the “sig-
nalosome” hypothesis, cardioprotective [e.g., G protein-coupled
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receptor (GPCR)-induced or ouabain-induced] signals are de-
livered to mitochondria by specialized caveolae-derived vesicular
structures, signalosomes, which contain a wide variety of receptors
(e.g., GPCRs) and signaling molecules (e.g., Akt, Src, eNOS, and
PKCe) that are assembled in lipid rafts and caveolae (17). In recent
years, the role of lipid rafts and caveolae in cardiovascular signaling
has attracted much attention (18), and adenylyl cyclases and PDEs
have emerged as key players in shaping and organizing intracellular
signaling microdomains (19-21).
Accumulating evidence implicates the mitochondrial perme-
ability transition (MPT) pore as a key effector of cardioprotection
against I/R injury, and reperfusion-induced elevation of reactive
oxygen species (ROS) can trigger the opening of the MPT pore,
resulting in ischemic injury, apoptosis, and cell death (16). A wide
range of cardioprotective signaling pathways converge on glycogen
synthase kinase-3β (GSK-3β), and its inhibition directly and/or
indirectly regulates MPT pore-regulatory factors (e.g., cyclophilin
D and voltage-dependent anion channels) and antiapoptotic Bcl-2
family members (22). Physical association between mitochondria
and the endoplasmic reticulum (ER) [via mitochondria-associated
ER membranes (MAMs)] (23) or the SR (24) also may reduce
reperfusion-induced mitochondrial Ca2+ overload and consequent
oxidative stress and thus block MPT pore opening (25).
In this study, we report that, 24 h after in vivo coronary artery
ligation, I/R or, in a Langendorff cardiac I/R model system, infarct
size is reduced in PDE3B−/− heart, but not in PDE3A−/− heart,
compared with WT heart. This protective effect is most likely
caused by reduced production of ROS and reduced Ca2+-induced
MPT pore opening in PDE3B−/− mitochondria. The mechanism(s)
for cardioprotection in PDE3B−/−mice may be related to cAMP/
PKA-induced opening of mitoKCa channels and assembly of
ischemia-induced caveolin-3–enriched fraction (ICEF) signalosomes
in which various cardioprotective molecules accumulate, resulting
in functional cardiac preconditioning. Our results also suggest
that the increased physical interaction between mitochondria
and transverse tubules (T-tubules) (indirectly via the SR at
dyads or directly) in PDE3B−/− heart may be involved in ICEF/
signalosome delivery of cardioprotective molecules to mitochon-
dria, leading to reduced ROS generation and increased resistance
to Ca2+-induced MPT pore opening in PDE3B−/− mitochondria.
Although PDE3A is more highly expressed than PDE3B in car-
diovascular tissues, our findings of cardioprotection against I/R
injury in PDE3B−/− mice but not in PDE3A−/− mice and the differ-
ent subcellular locations of PDE3A and PDE3B in cardiomyocytes
[PDE3A colocalizes with sarco/endoplasmic reticulum Ca2+-
ATPase (SERCA) on SR membranes, and PDE3B localizes with
caveolin-3 in T-tubules along Z-lines] may reflect an important
example of individual PDEs at distinct subcellular sites regulating
the compartmentalization of specific cAMP/PKA-signaling path-
ways (19, 21). In this case, PDE3B, located in regions where
cardiomyocyte mitochondria, T-tubules, and SR may be in close
proximity, may regulate stress responses and/or the assembly of
ICEF signalosomes or other specific cardioprotective pathways.
Results
Targeted Disruption of PDE3B Is Cardioprotective in a cAMP/PKA-
Dependent Manner. As shown in Figs. 1 and 2, in vivo coronary
artery ligation I/R (Fig. 1) and the Langendorff-perfused heart I/R
model (Fig. 2), respectively, were used to investigate the effects of
targeted disruption of PDE3B on I/R injury. Compared with WT
heart, I/R-related infarct size after in vivo I/R was reduced in
PDE3B−/− heart but not in PDE3A−/− heart (Fig. 1 A–C). Ad-
ministration of milrinone, a PDE3 inhibitor, to mice before in vivo
I/R reduced infarct size in WT and PDE3A−/− hearts but did not
further enhance protection in PDE3B−/− mice (Fig. 1 D and E).
As shown in Fig. 2, after in vitro I/R was performed according to
the I/R protocol depicted in Fig. 2 A, i, I/R-induced infarct size
also was reduced in Langendorff-perfused PDE3B−/− hearts,
compared with WT (Fig. 2 B and C). Consistent with the reduced
infarct size, functional recovery also was increased significantly in
PDE3B−/− hearts. As shown in Fig. 2D, the rate pressure product
(RPP) [RPP = left ventricular developed pressure (LVDP) ×
heart rate] after 25 min of ischemia and 1.5 h of reperfusion was
significantly greater in PDE3B−/− heart than in WT heart, i.e.,
56.3 ± 4.5% (n = 8) of preischemic RPP in PDE3B−/− heart
compared with only 23.0 ± 4.4% (n = 6) of preischemic RPP in
WT heart. As seen in Table S1, hemodynamic parameters mea-
sured before and after I/R of Langendorff-perfused hearts from
WT, PDE3B−/−, and PDE3A−/− mice indicated that the higher
RPP in perfused PDE3B−/− hearts after I/R injury was associated
with higher LVDP in PDE3B−/− hearts. Consistent with the ab-
sence of cardioprotection in vivo (Fig. 1), PDE3A−/− heart did
not exhibit improved postischemic recovery in vitro (Fig. 2E).
Taken together, these results (Figs. 1 and 2) strongly suggest that
inhibition of PDE3B, but not of PDE3A, is responsible for the
reported cardioprotective effects of PDE3 inhibitors in earlier I/R
studies (6–9).
In Western blots, PDE3A was much more highly expressed in
heart extracts than in WAT extracts (Fig. S1A), whereas PDE3B
was more highly expressed in WAT. PDE3B protein was not ex-
pressed in either WAT or heart extracts from PDE3B−/− mice.
Targeted disruption of PDE3B slightly increased the expression of
PDE3A inWAT but not in heart, suggesting that cardioprotection
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Fig. 1. PDE3B−/− mice, but not PDE3A−/− mice, have smaller infarcts after in
vivo coronary artery occlusion/reperfusion, compared with WT mice. Mice
were subjected to 30 min of in vivo coronary artery ligation followed by 24-h
reperfusion as described in SI Experimental Procedures. (A) Representative
sections of myocardium from WT, PDE3B−/− (3B KO), or PDE3A−/− (3A KO)
mice in which I/R-induced myocardial infarction was determined by Evans
blue/ triphenyl tetrazolium chloride (TTC) double staining. (B) Myocardial
infarct size was expressed as a percentage of the infarct area over the is-
chemic risk zone. (C) The size of the ischemic risk zone was expressed as the
percentage of ischemic risk zone over total ventricular area. Results are
means ± SEM, n = 4–9 animals per group. ***P < 0.001 3B KO vs. WT. (D and
E) Infarct size (D) and size of the area at risk (AAR) (E) from WT, 3A KO, or
3B KO mice treated with saline or milrinone before I/R, as described in SI
Experimental Procedures. *P < 0 0.05 vs. WT + saline; †P < 0.05 vs. WT + mil-
rinone; ‡P < 0.05 vs. 3A KO + saline by one-way ANOVA with Student–
Newman–Keul post hoc correction. n = 3–6 animals per group.
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in PDE3B−/− heart was not related to compensatory increased
expression of cardiomyocyte PDE3A. Although cAMP was sig-
nificantly increased in PDE3B−/− heart (Fig. 2F), there were no
significant changes in either cAMP content (Fig. 2G) in PDE3A−/−
heart or cGMP content in PDE3B−/− heart (Fig. S2A), compared
with WT. As indicated in Fig. 2A, to study the effects of PKA
inhibitor on I/R injury, hearts were perfused with oxygenated
buffer containing the PKA inhibitor KT5720 before induction of
I/R. As seen in Fig. 2 H and I, the cardioprotective effect in
PDE3B−/− hearts was blocked significantly by KT5720 at con-
centrations of 0.5 and 1 μM with respect to RPP (Fig. 2H) and at
0.25, 0.5, and 1 μM with respect to infarct size (Fig. 2I). Con-
sistent with these inhibitory effects of the PKA inhibitor KT5720
(Fig. 2 H and I) and increased cAMP content (Fig. 2F), PKA-
induced phosphorylation of several substrates was increased in
PDE3B−/− heart (Fig. S1B). The observation that cardioprotection
in PDE3B−/− heart is PKA dependent is consistent with a prior
report which indicated that PKA regulates the opening of the
mitoKCa channel (13) and with the significant inhibition of RPP
in PDE3B−/− heart by the mitoKCa channel inhibitor paxilline
(Fig. S2C).
Localization of Cardiac PDE3B and PDE3A. We performed cryo-
immunogold electron microscopy (EM) to determine where
PDE3B and PDE3A are localized in cardiomyocytes. PDE3B-
specific labeling was concentrated in the I-band of the sarco-
mere, consistent with localization to dyads, T-tubules, or the
highly elaborated (corbular) SR of the I-band (Fig. 3 B–D).
Caveolin-3, a caveolae protein, is found in both caveolae and
T-tubules in heart muscle (26). Double immunogold labeling
with PDE3B antibody and caveolin-3 antibody suggested colocali-
zation of the two proteins along the Z-line and on or near T-tubule
membranes (Fig. 3B), some of which were in contact with mito-
chondria (Fig. 3C). Measurement of the distance between 10-nm
gold particles representing caveolin-3 localization and 15-nm
particles representing PDE3B localization were consistent with
T-tubule localization of PDE3B (Fig. 3E). Because deletion of
PDE3A did not confer a cardioprotective effect on heart muscle,
we suspected that its subcellular distribution might be different
from the T-tubule localization of PDE3B. Initial cryo-immunogold
EM revealed a distribution of PDE3A immunoreactivity primarily
consistent with SR localization. This distribution was confirmed by
double cryo-immunogold labeling with antibodies against PDE3A
and SERCA2, a marker for the SR (Fig. 3 F and G). The dis-
tribution of immunoreactivity for PDE3A and SERCA2 was highly
similar, and they were closely colocalized with a high frequency.
This EM localization of PDE3A and SERCA2 is consistent with
our recent immunohistochemical localization of murine cardiac
PDE3A (27). As seen in Fig. S3, PDE3A colocalized with SERCA2
in PDE3B−/− hearts, as in WT hearts. Fig. 3H is a diagrammatic
representation of the distribution of PDE3A and PDE3B in WT
heart, based on our immunogold labeling results.
PDE3B−/− Cardiac Mitochondria Contact T-Tubules More Frequently
and Produce Less ROS. Overexpression of caveolin-3 increases the
formation of caveolae and induces cardiac protection by mimicking
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Fig. 2. PDE3B−/−-specific cardioprotection against I/R injury is PKA dependent. (A) Experimental protocols. Hearts were prepared as described in SI Experi-
mental Procedures, and I/R was performed according to the I/R protocol depicted. Initial LVDP was measured at time 0 (arrowhead). The arrow indicates the
time point at which postischemic LVDP recovery was measured. Hearts were stained with 1% TTC to analyze infarct size, and I/R samples were collected for
further analysis. (B) Representative sections of myocardium from WT or PDE3B−/− mice (3B KO), stained with TTC to delineate areas of infarction. (C) Infarct
size (white areas) is presented as percent of total ventricular area. Results are means ± SEM; n = 4–9 animals per group. (D and E) After I/R (see the I/R protocol
in A), RPPs of PDE3B−/− (3B KO, male) (D) and PDE3A−/− (3A KO, female) (E) mice are presented as percent of initial RPP. n = 4–8 animals per group. (F and G)
The concentrations of cAMP in PDE3B−/− (F) and PDE3A−/− (G) hearts were determined as described in SI Experimental Procedures. Results are shown as means ±
SEM; n = 7–20 animals per group. (H and I), PDE3B−/− hearts were perfused with vehicle (0.1% DMSO) or the PKA inhibitor KT5720 (0.25, 0.5, or 1 μM), according to
the I/R protocol depicted in A. (H) RPP values are expressed as percentages of initial RPP. (I) Infarct size is presented as percent of total ventricular area. Results are
means ± SEM; *P < 0.05; ***P < 0.001 vs. DMSO-treated PDE3B−/− by ANOVA. n = 3–6 animals per group.
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preconditioning (28). Increased expression of caveolin-3 in
cardiac mitochondria was associated with enhanced respiratory
function, reduced generation of ROS, and reduced infarct size
during in vitro I/R (29). Conversely, caveolin-3−/− mice show very
low caveolar density (30) and are resistant to pharmacological
preconditioning (31). Given the colocalization of PDE3B with
caveolin-3 on or near T-tubule membranes in cardiomyocytes (Fig.
3 B and C), we examined the location and number of caveolae but
were surprised to find no differences in the number of caveolae
identified in electron micrographs from WT and PDE3B−/− heart
(Fig. S4A). Moreover, there was no difference in the number of
caveolae in contact with mitochondria close to the sarcolemma.
However, as seen in Fig. S4 A and B, in PDE3B−/− heart there was
a small, not statistically significant, increase in the number of
T-tubule profiles in contact with category IV mitochondria
within the sarcoplasm one myofibril deep from the sarcolemma.
There were no significant differences between WT and PDE3B−/−
heart in mitochondria numbers (Fig. S4C) or in the ratio of mito-
chondrial DNA (mtDNA) to nuclear DNA (nDNA) (Fig. S4D).
Because the number of category IV contacts seemed to be greater
in PDE3B−/− heart, we counted all contacts between mitochondria
and SR/T-tubule junctions (dyads) or directly with T-tubules,
areas where PDE3B and caveolin-3 colocalize. These contacts were
increased significantly in electron micrographs from PDE3B−/−
compared with WT hearts (Fig. 4 A–C) and perhaps were related
to a role for caveolin-3 in the development of the cardioprotective
phenotype and signs of preconditioning in PDE3B−/− hearts, in-
cluding (as described below) reduced ROS (Fig. 4D) and increased
resistance to Ca2+-induced opening of the MPT pore in the “light”
mitochondrial (LM) fraction (Fig. 5C) (29).
As described in SI Experimental Procedures and shown in Fig.
5A, total mitochondria (P2 fractions) were isolated from WT and
PDE3B−/− hearts before and after ischemia to assess ROS pro-
duction. P2 mitochondrial fractions (pellets after centrifugation
at 10,000 × g) represent total mitochondria, which include LM
and “heavy” mitochondrial (HM) fractions. As shown in Fig. 4D,
after ischemia, production of ROS was markedly reduced in total
mitochondria (P2 fractions) from PDE3B−/− heart, compared
with WT mitochondria. These results are consistent with
the significant inhibition of RPP in PDE3B−/− heart by the
PI3K inhibitor wortmannin (Fig. S2C) and with the increased
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Fig. 3. Different localization of PDE3A and PDE3B in cardiomyocytes.
(A) Conventional transmission electron microscopy (TEM) images of a lon-
gitudinal section of a myocyte showing relationships between T-tubules (t),
SR (s), and mitochondria (m) around the Z-line (z). (B and C) Representative
images of immunogold labeling of caveolin-3 (10-nm particles) and PDE3B
(15-nm particles, arrows). (B) Particles of both sizes are concentrated in the
I-band along the Z-line and on or near T-tubule membranes. (C) An example
of PDE3B labeling close to caveolin-3 labeling on a T-tubule in contact with a
mitochondrion. (D) The density of 15-nm gold particles (PDE3B) in the
A-band and I-band was measured. The dotted line indicates the level of
nonspecific labeling. (PDE3B−/− heart muscle was used as a control for non-
specific labeling.) Results are means ± SEM; ***P < 0.001 vs. WT. EM images (n =
43–66 per group) were used for counting. (E) Histogram showing the frequency
of the distance of 15-nm gold particles representing specific PDE3B labeling
from the nearest 10-nm particle representing caveolin-3 labeling. The frequency
in each range of nonspecific 15-nm gold labeling was subtracted from the total.
(F and G) Representative images of immunogold labeling of SERCA2 (10-nm
particles) and PDE3A (5-nm particles, arrows). Particles of both sizes are con-
centrated on the SR, both at the dyads with T-tubules (F) and along the myo-
fibrils and mitochondria (G). (H) Diagrammatic representation of a cardiac
myocyte sarcomere with associated membranous organelles, showing the
codistribution of PDE3B with caveolin-3 on T-tubule membranes (blue) along
the Z-line and within the I-band (I) and the codistribution of PDE3A with
SERCA2 on SR membranes (red) that span the I- and A-band (A). Mitochondria
are in close contact with both SR and T-tubules. (Scale bars, 200 nm.)
D
0.0
0.2
0.4
0.6
0.8
1.0
1.2
WT 3B KO
p=0.01
R
O
S 
pr
od
uc
tio
n 
(p
m
ol
s)
Time (minutes)
Sl
op
es
 (R
at
io
)
0
50
100
150
200
250
300
350
400
450
500
1 4 7 10 13 16 19 22 250       5            15      20      
WT + is
KO + is
E
Bcl-2
VDAC
B
cl
-2
/V
D
AC
0
2
4
6
8
10
WT 3B KO
*
0.0
0.5
1.0
1.5
WT 3B KO
Sl
op
es
 (R
at
io
)
p=0.03
basal ROS level
WT
KO
M
ito
ch
on
dr
ia
 a
tta
ch
ed
 to
SR
/T
-tu
bu
le
 in
 3
5.
1 
µm
2
0
2
4
6
8
10
12
WT 3B KO
***
CA B
t
c c
m
sc
s
s
m
sc
m
m
m
t
t s
Fig. 4. PDE3B−/− cardiac mitochondria contact T-tubules more frequently and
produce less ROS. (A–C) Conventional TEM images demonstrating interactions
between mitochondria, dyad junctions, and T-tubules. (A and B) Cross-sections
of cardiomyocytes near the Z-line. c, caveolae; m, mitochondrion; s, SR; sc,
sarcolemma; t, T-tubule. Contacts of mitochondria with dyad junctions (A) and
directly with T-tubules (B) can be seen. (C) Average numbers of mitochondria
attached to dyad junctions or directly to T-tubules per 35.1 μm2 of sarcoplasm.
EM images (n = 124–127 per group) were used for counting. Results are means
± SEM; ***P < 0.001 vs. WT. (Scale bar, 200 nm.) (D) As described in SI Ex-
perimental Procedures, averaged traces of ROS production were measured in
the presence of glutamate/malate and ADP by monitoring the oxidation of
Amplex Red in WT and PDE3B−/− heart mitochondria fractions isolated after
ischemia. Ratios of slopes for rates of ROS production by WT and PDE3B−/− (3B
KO) heart mitochondria are presented as bar graphs, with WT as 1. (Inset )
Basal production of ROS in WT and PDE3B−/− heart mitochondria. n = 3–4 mice
per group. (E) WT and PDE3B−/−mitochondrial fractions after I/R were used for
Western blotting of Bcl-2. The ratio of Bcl-2/voltage-dependent anion channel
(VDAC) is mean ± SEM; *P < 0.05 vs. WT, n = 4 animals per group.
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phosphorylation of Akt and GSK-3β in PDE3B−/− heart (Fig. S2
D and E). Previous studies have demonstrated that GSK-3β–
regulated protection against MPT pore opening is associated
with reduced production of ROS (22, 32).
Western blot analysis of heart mitochondrial fractions revealed
that antiapoptotic Bcl-2 was increased significantly in PDE3B−/−
heart after I/R (Fig. 4E). Consistent with these protective changes,
phosphorylation of cAMP response element-binding protein
(CREB) and expression of the proapoptotic CREB antagonist,
inducible cAMP early repressor (ICER) (33), were not elevated in
PDE3B−/− heart but were similar to WT (Fig. S1C). We previously
reported (27) that, compared with WT heart, phosphorylation of
CREB, phospholamban, and other substrates of PKA was in-
creased in PDE3A−/− heart, which did not exhibit cardioprotection
during I/R (Figs. 1 and 2). As seen in Fig. S1D, expression of
proapoptotic ICER was increased in PDE3A−/− heart compared
with WT heart. Yan et al. (33) have suggested that increased
phosphorylation/activation of CREB is an important factor in the
up-regulation of ICER expression and subsequent proapoptotic
changes (33), which could be a factor in the lack of cardio-
protection in PDE3A−/− heart during I/R (Figs. 1 and 2).
Mitochondrial Fractions Isolated from PDE3B−/− Hearts Are More
Resistant to Ca2+-Induced MPT Pore Opening. To assess Ca2+-induced
swelling, LM and HM fractions were isolated from WT and
PDE3B−/−mitochondrial P2 fractions (Fig. 5A and SI Experimental
Procedures) and analyzed by Western blotting (Fig. 5B). The LM
fraction contained caveolin-3 and connexin-43, which are con-
sidered to be subsarcolemmal mitochondria (SSM)-specific
proteins (29, 34). Connexin-43 is increased in cardiomyocyte
mitochondria during preconditioning (35) and may be critical in
protection against myocardial I/R injury (36). LM fractions also
contained binding immunoglobulin protein (BiP), an ER marker
protein (Fig. 5B). The amount of caveolin-3 and connexin-43 in
LM fractions increased during ischemia (Fig. 5B). As seen in the
lower trace in Fig. 5C, the HM fraction underwent MPT pore
opening as indicated by Ca2+-induced swelling, which resulted in
a decrease in absorbance at 540 nm. In general, LM fractions
were more resistant than HM fractions to Ca2+-induced swelling.
LM fractions from PDE3B−/− heart, however, were significantly
more resistant than LM fractions fromWT heart (Fig. 5C, Upper).
It is possible that both HM and LM fractions contain SSM, or the
LM fraction may be a portion of SSM, which are enriched in
caveolin-3 and connexin-43 and are in close proximity to plasma
membranes or ER/SR membranes (29). The characteristics of the
LM fraction observed here, however, are quite different from those
of the SSM described previously (34), especially regarding sensitivity
to calcium (Fig. 5C) (37).
Because LM fractions were enriched in caveolin-3 and con-
nexin-43, we investigated whether these fractions contained
specialized microdomains, such as lipid rafts and caveolae. The
location of connexin-43 in LM mitochondria isolated from WT
heart after ischemia was examined first by extracting caveolin-3
and connexin-43 from LM mitochondria with proteinase K, as
described in a previous study (34), and a nonionic detergent Triton
X-100 (TX-100). As shown in Fig. S5, however, these reagents did
not allow analysis of differential extraction of caveolin-3 and con-
nexin-43 from specific compartments, because treatment of the
LM fraction with proteinase K or TX-100 released caveolin-3 and
connexin-43 not only with proteins from the outer membranes
of mitochondria (OMM) but also with proteins from the inner
membranes of mitochondria (IMM). Because different cellular
membranes contain different amounts of cholesterol [which is
more abundant in plasma membranes than in the mitochondrial
membranes (38)], and caveolae are cholesterol- and sphingolipid-
enriched invaginations of the plasma membrane (39), cholesterol-
removing detergents such as methyl-β-cyclodextrin (MβCD) or
digitonin also were used for extraction of caveolin-3 and connexin-43.
As shown in Fig. 5D, at concentrations of 25 and 50 mM MβCD,
or 0.003–0.025% digitonin, caveolin-3 and connexin-43 were
extracted from the LM fraction, accompanied by little or no
release of mitochondrial proteins from the OMM or other in-
ternal mitochondrial compartments. Although it has been sug-
gested that connexin-43 is located in the IMM (34), these results
suggested that connexin-43 might be located in cholesterol-enriched
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Fig. 5. PDE3B−/− cardiac mitochondrial fractions which contain connexin-43
and caveolin-3 (LM fractions) are more resistant to Ca2+-induced MPT pore
opening. (A) Schematic representation of procedures for isolation of mito-
chondrial fractions, as described in SI Experimental Procedures. P1, pellet no. 1
after the first spin (500 × g); P2, pellet no. 2 after the second spin (10,000 × g); S,
supernatant after the first spin (500 × g). (B) As described in SI Experimental
Procedures, LM and HM fractions were separated from P2 mitochondrial
fractions by differential centrifugation. Shown are Western blots of LM and
HM fractions isolated from WT (W) and PDE3B−/− (K) hearts before (perfusion
only, P) and after (is) ischemia. Western blots (30 μg protein per lane) were
performed with antibodies against a gap junction protein connexin-43 (Cx43);
caveolin-3 (Cav-3); an ER marker, 78-kDa chaperone BiP/GRP78 (BiP); and a
mitochondria marker, VDAC. (C) As described in SI Experimental Procedures,
MPT pore formation was measured as the change in absorbance at 540 nm
after stimulation with 400 μM Ca2+ (arrow). Results are means ± SEM; n = 4–6
animals per group. **P < 0.01 vs. WT LM. n.s., not significant. (D) Extraction of
connexin-43 and caveolin-3 from LM fractions by membrane-disruption
assays. (Upper Left) As described in SI Experimental Procedures, after is-
chemia, LM fractions were separated from mitochondrial P2 fractions and
incubated for 5 min with the cholesterol-removing detergents digitonin
(0.002–0.1%) and MβCD (1–50 mM) in serially diluted concentrations, as
shown in the table (Right). After centrifugation (10,000 × g, 5 min), super-
natants were discarded, and pellets were analyzed by Western blotting
(30 μg protein per lane). c, control; Cav-3, caveolin-3; Cx43, connexin-43;
IMAP, inner membrane associated protein; matrix, mitochondrial matrix
protein; Vα, ATP synthase (Complex V) subunit α; VDAC, mitochondria
marker. (Lower Left) Gels were stained with Coomassie blue after transfer.
The experiments in C and D were repeated with 4–6 mice per group.
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microdomains, perhaps in caveolin-3–enriched caveolae/signal-
osomes attached to or in close proximity to the OMM.
Isolation and Proteomic Analysis of ICEFs. To isolate mitochondria-
associated caveolae/signalosomes, we modified the well-estab-
lished isolation methods for caveolae (39) and signalosomes
(17). As shown in Fig. 5A and Fig. S6A, the mitochondrial P2
pellet was fractionated further by stepwise sucrose gradient ul-
tracentrifugation [35, 40, and 45% (wt/vol) sucrose layers] to
isolate buoyant fractions, designated as ICEFs. As seen in Fig.
S6B, ICEFs contained caveolin-1 and caveolin-3, and the
caveolin-3 content of ICEFs increased markedly during ischemia.
A comprehensive proteomic characterization of ICEFs iso-
lated from WT and PDE3B−/− hearts before/after ischemia, using
isobaric tag for relative and absolute quantification (iTRAQ),
identified more than 500 proteins, most of which were mitochon-
drial (Fig. S6C). To identify possible biological pathways in ICEF
proteomes, we used the Database for Annotation, Visualization
and Integrated Discovery (DAVID) 6.7 tool to analyze Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways. Al-
though only the cardiac muscle contraction pathway was enriched
in the top 10 pathways, three other cardiac function-related path-
ways also were enriched significantly: arrhythmogenic right ven-
tricular cardiomyopathy, dilated cardiomyopathy, and hypertrophic
cardiomyopathy (Fig. S6D).
Table S2 lists 57 ICEF proteins in which at least one of three
ratios was significantly different: (i) between PDE3B−/− and WT
before ischemia (KO/WT); (ii) between WT after ischemia and
WT before ischemia (WT+is/WT); and (iii) between PDE3B−/−
after ischemia and PDE3B−/− before ischemia (KO+is/KO).
Interestingly, as seen in Fig. 6A, the ICEF proteome contains
three components of dysferlin-mediated membrane repair ma-
chinery (40), i.e., dysferlin, annexin A2, and the newly described
tripartite motif family protein (TRIM72) (41), as well as calcium-
signaling proteins, SERCA2, calnexin, calsequestrin-2, cadherin-13,
and sarcalumenin (Fig. S7). The iTRAQ results (Fig. 6A and
Table S2) indicated that, compared with ICEFs in WT heart,
many of these proteins were significantly enriched in ICEFs of
PDE3B−/− heart before ischemia and increased further in ICEFs
of WT heart during ischemia; this finding is consistent with the
idea that PDE3B−/− heart might be functionally preconditioned.
The ICEF proteome also contains seven proteins (nos. 3, 6, 32,
34, 44, 46, and 47 in Fig. 6A and Table S2), thought to be possibly
cardioprotective and found in a larger group of proteins identi-
fied in a mitochondrial proteomic profile induced during the
exposure of perfused hearts to the GSK inhibitor SB216763 (42).
Western blot analysis confirmed that TRIM72 protein was
significantly enriched in ICEFs of PDE3B−/− heart before is-
chemia (Fig. 6 B and C). Although caveolin-3 and connexin-43
were not detected by iTRAQ, Western blots indicated that
their protein expression before ischemia, like that of TRIM72,
was increased in PDE3B−/− ICEFs compared with WT ICEFs
(Fig. 6B, Left). TRIM72, caveolin-3, and connexin-43 also were
increased in ICEFs during preconditioning of WT hearts
(Fig. 6B, Right). Accumulation of caveolin-3 and connexin-43 in
ICEFs increased further during ischemia and to a greater extent
than TRIM72 (Fig. 6B, Left, and Fig. 6C). Furthermore, as seen
in Fig. 6 D and E, exposure to the PKA inhibitor KT5720 largely
blocked the accumulation of these proteins in PDE3B−/− ICEFs
during ischemia, whereas the PKG inhibitor KT5823 and the P13K
inhibitor wortmannin did not, suggesting that ICEF assembly is
PKA dependent. As shown in Fig. 6F, a similar accumulation of
these proteins was observed in the ICEFs of cilostamide-treatedWT
hearts after perfused hearts were incubated with the potent PDE3
inhibitor cilostamide according to the cilostamide inhibitor protocol
in Fig. 2A.
Functional annotation with Gene Ontology (GO), using the
DAVID functional annotation tool (david.abcc.ncifcrf.gov)
A No. Identified Proteins KO / WT WT+is / WT KO+is / KO n Related Pathways Ref
4 Annexin A2 1.30 ± 0.12† 1.39 ± 0.16† 1.04 ± 0.10 6 Dysferlin-mediated
membrane repair
machinery
40,4120 Dysferlin 1.38 ± 0.12* 1.47 ± 0.16 1.06 ± 0.06 4
57 Tripartite motif-containing protein 72 1.53 ± 0.14* 1.63 ± 0.18* 0.98 ± 0.10 4
3 Fructose-bisphosphate aldolase A 1.15 ± 0.08 1.70 ± 0.17* 1.47 ± 0.12** 6
GSK-dependent
cardioprotection
(mitochondrial)
42
6 Annexin A6 1.32 ± 0.13 2.09 ± 0.31* 1.31 ± 0.22 6
32 Heat shock protein HSP 90-beta 1.26 ± 0.10 1.71 ± 0.20* 1.33 ± 0.11* 6
34 Heat shock cognate 71 kDa protein 1.29 ± 0.10* 1.70 ± 0.27* 1.42 ± 0.11* 6
44 6-phosphofructokinase, muscle type 1.08 ± 0.07 1.51 ± 0.16* 1.37 ± 0.13* 6
46 Phosphoglycerate kinase 1 0.95 ± 0.06 1.11 ± 0.13 1.57 ± 0.03*** 4
47 Pyruvate kinase isozymes M1/M2 1.45 ± 0.09 2.37 ± 0.27* 1.62 ± 0.12** 6
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Fig. 6. Accumulation of proteins into ICEFs is PKA dependent. (A) Representative list of protective proteins (components of membrane-repair machinery and
proteins in the mitochondrial fraction increased during treatment with a GSK inhibitor) among the 57 ICEF proteins selected by P < 0.06, with relative fold
changes compared by iTRAQ between WT and PDE3B KO cells before and after (+is) ischemia. Values are normalized by an average of VDAC-1, VDAC-2, and
VDAC-3. Results are means ± SEM. †P < 0.06; *P < 0.05; **P < 0.01; ***P < 0.001. n = number of independent experiments. The 57 proteins are listed in Table
S2. (B, Left) Representative Western blots of ICEFs isolated from WT and PDE3B−/− heart before and after (+Is) ischemia for 25 min according to the I/R
protocol (no reperfusion) depicted in Fig. 2A. (Right) ICEFs isolated from WT hearts either after preconditioning (PreC) or after preconditioning followed by
ischemia (PreC + Is) according to the PreC protocol depicted in Fig. 2A. (C) Bar graphs showing relative changes in several ICEF proteins in WT and PDE3B−/−
hearts before and after ischemia (Is) (B, Left). Results are means ± SEM. *P < 0.05; †P < 0.06; **P < 0.01 vs. WT before ischemia. (D) Western blots of ICEFs
isolated from PDE3B−/− hearts perfused in the presence of 1 μM KT5720, 1 μM KT5823, or 100 nM wortmannin, followed by ischemia for 25 min according to
the I/R protocol (no reperfusion) depicted in Fig. 2A. (E) Fold changes are shown as means ± SEM. *P < 0.05 vs. DMSO. (F) ICEFs were isolated from WT hearts
after perfusion with the selective PDE3 inhibitor cilostamide (1 μM) for 30 min according to the cilostamide protocol depicted in Fig. 2A. Western blots in B
and D (30 μg protein per lane) were incubated with antibodies against caveolin-3, connexin-43, TRIM72, and VDAC. In C, E, and F, the intensity of blots is
presented as relative fold changes normalized by the intensity of VDAC. Results are means ± SEM; n = 4–9 animals per group.
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suggested that the differentially accumulated proteins in ICEFs
could be divided into three categories of GO annotations: cellular
component, molecular function, and biological process (Table S3).
To identify the underlying biological function further, the differ-
entially accumulated 57 ICEF proteins were imported into the
Cytoscape tool. Then GO analysis was performed with the BiNGO
tool (Fig. S8A). It was of interest that we found Z disk and I band
of subcluster no. 2 (sarcomere), which are linked to subcluster
no. 1 (mitochondria) via subcluster no. 3 (organelle), suggesting an
ICEF-mediated interaction between mitochondria and sarco-
meres (Z disk and I band). Consistent with EM data (Figs. 3 and 4
A and B) and iTRAQ data, Western blots indicated that the SR
marker protein calsequestrin was highly enriched in ICEFs from
PDE3B−/− heart (compared with WT heart) together with
T-tubule L-type Ca2+ channel (CaV1.2) (Fig. S8 B–D). During
ischemia, accumulation of Cav 1.2 and calsequestrin in ICEFs,
similar to that of TRIM72 (Fig. 6D), was blocked by the PKA
inhibitor KT5720 but not by the PI3K inhibitor wortmannin or
the PKG inhibitor KT5823 (Fig. S8E).
Discussion
Studies with PDE3A−/− and PDE3B−/− mice have been in-
formative in delineating specific functional roles for PDE3A and
PDE3B isoforms that may be relevant to human physiological
and pathophysiological processes. PDE3A, for example, regulates
platelet aggregation and basal myocardial contractility (43), as well
as cell-cycle progression in oocytes [female PDE3A−/−mice, but
not female PDE3B−/− mice, are infertile (3)] and murine vascular
smooth muscle cells (44). This latter work supports a possible role
for PDE3A, but not for PDE3B, in modulating poststenting or
postangioplasty vascular remodeling and suggests that the in-
hibition of PDE3A mediates some of the reported beneficial
effects of cilostazol, a PDE3 inhibitor, in reducing poststenting
restenosis and progression of carotid intima-media thickness in
some patients (45, 46). Earlier work with PDE3B−/− mice sug-
gested that PDE3B regulates energy metabolism (4), and we
recently reported that in PDE3B KO mice WAT assumes phe-
notypic characteristics of BAT (47).
The results presented here with PDE3B−/− mice strongly
suggest that PDE3B is the isoform responsible for the car-
dioprotective effects against I/R injury associated with the phar-
macological inhibition of PDE3 (6–9). These studies also indicate,
for the first time to our knowledge, distinct subcellular locations of
PDE3A and PDE3B in cardiomyocytes, with PDE3A distributed
with SERCA2 on SR membranes and PDE3B colocalizing with
caveolin-3 along the Z-line and on or near T-tubule membranes,
close to mitochondria (Fig. 3B). PDE3B may be a unique PDE in
these areas, where it may play an important role in regulating
compartmentalized cAMP-signaling pathways (1, 19, 21, 48, 49).
The observation that cAMP is increased in PDE3B−/−hearts but
not in PDE3A−/−hearts (Fig. 2 F andG) suggests that PDE3B may
regulate a pool of cAMP that is not readily accessed by other
PDEs. However PDE3A may share compartments with other
PDEs, especially PDE4 (50, 51). For example, PDE3A, PDE4A,
and PDE4B are recruited to PI3Kγ- and PKA-based multimo-
lecular complexes in murine cardiomyocytes. In these complexes
they are activated by PKA and thereby block, in a feed-back
fashion, cAMP/PKA-initiated and Ca2+-dependent ventricular
arrhythmias; these PDEs could exist in the same compartment or
in unique or functionally overlapping ones (51).
The increased cAMP (Fig. 2F) and phosphorylation of several
PKA substrates (but not CREB) (Fig. S1 B and C), as well as the
inhibitory effects of the PKA inhibitor KT5720 on RPP (Fig.
2H), infarct size (Fig. 2I), and assembly of ICEF signalosomes
(Fig. 6D and Fig. S8E), in PBE3B−/− heart, suggest that car-
dioprotection may be regulated via compartmentalized cAMP/
PKA-signaling pathways. The increase in cAMP content and ac-
tivation of PKA may enhance the assembly of ICEF/signalosomes
and localized PKA-dependent opening of mitoKCa channels (Fig.
S2C, paxilline) and thereby protect the PDE3B−/−heart from I/R
injury. Compared with WT, PDE3B−/− cardiac mitochondria frac-
tions are preconditioned, in that they contain more cardioprotective
ICEF proteins, produce less ROS, and are more resistant to Ca2+-
induced MPT pore opening.
We cannot exclude the possibility that cGMP/PKG-signaling
pathways also are involved in cardioprotective mechanisms in
PDE3B−/− mice in a manner that suggests cAMP- and cGMP-
signaling cross talk. The significant inhibition of RPP in PDE3B−/−
heart by the PI3K inhibitor wortmannin and the PKG inhibitor
KT5823 [by 52.4% and 35.3%, respectively, compared with DMSO
(Fig. S2C)] suggested that cardioprotection also may be regulated
via PI3K/Akt/eNOS/PKG-signaling pathways, in which cGMP and
nitric oxide might play an important role, or the PI3K/Akt/GSK-3β
pathway, which also is known as the “reperfusion injury salvage
kinase” pathway (16). Because the eNOS inhibitor L-NG-nitro-
arginine methyl ester (L-NAME) did not block the beneficial effect
of PDE3B ablation on RPP (Fig. S2B), and no changes in cGMP
levels (Fig. S2A) or in phosphorylation of eNOS by Western blot
analysis (Fig. S2F) were observed, the case for the PI3K/Akt/GSK-3β
pathway seems more convincing. This notion was supported by
the increased level of phosphorylated Akt (Fig. S2D) and phos-
phorylated GSK-3β (Fig. S2E) in PDE3B−/− heart and is consis-
tent with published results of others (52) which indicated
that, during preconditioning, GSK-3β was phosphorylated and
inhibited in a wortmannin-sensitive manner. GSK-3β is an in-
tegration point of various cardioprotective signaling pathways
which ultimately prevent MPT pore opening (22). A role for
phosphorylated GSK-3β in cardioprotection of PDE3B−/− heart
also is supported by the increased expression of antiapoptotic
Bcl2 (Fig. 4E) and the PDE3B−/− ICEF proteome, which in-
cludes proteins that are induced by inhibition of GSK-3β (Fig. 6A
and Table S2) and are thought to be cardioprotective (42). It is
of interest that phosphorylation of GSK-3β and up-regulation of
Bcl-2 also were observed in I/R hearts perfused with the PDE5
inhibitor sildenafil (53), and it has been further suggested that
the cardioprotective effects of sildenafil are mediated by acti-
vation of both mitoKATP (10) and mitoKCa channels (11).
Interestingly, the association of four ICEF proteins [fructose-
bisphosphate aldolase A, annexin A6, heat-shock cognate 71 kDa
protein (HSC70), and pyruvate kinase isozymes M1/M2] with
mitochondria also was reported to be blocked significantly by the
heat-shock protein 90 (HSP90) inhibitor geldanamycin (42), sug-
gesting that at least some ICEF proteins may be transported into
mitochondria via the HSC70-HSP90-TOM70 system (HSC70
and HSP90 are found in ICEFs) (54). It also has been sug-
gested that mitochondrial connexin-43 translocates to IMM
through the HSP90-dependent translocase complex of the outer
mitochondrial membrane (TOM) pathway (36) and plays a crucial
role in cardioprotection associated with the PI3K/Akt/GSK-3β
pathways (55). In PDE3B−/− heart the improved postischemic
recovery of RPP was inhibited significantly by blocking the PKA-
dependent mitoKCa channel opening by paxilline (Fig. S2C).
This observation was consistent with the reported effects of
cilostazol on the PKA-regulated mitoKCa channel (8) but not with
mitoKATP channel blocking by 5-hydroxydecanoic acid (5-HD),
which is PKG/PKC dependent (Fig. S2C). The results of our studies
with paxilline and 5-HD, which suggest that cardioprotection
may be related to cAMP/PKA-induced activation of the mitoKCa
channel, are consistent with other studies discussed in this re-
port, i.e., the effects of PKA and PKG inhibitors (Figs. 2 H and I
and 6D and Figs. S2C and S8E) and the effects of the PDE3
inhibitor cilostamide (Fig. 6F). However, because paxilline and
5-HD (or other pharmacological agents) are not completely
specific for ion channels (or other targets), interpretation of studies
that use pharmacological agents should be tempered by the pos-
sibility of off-target effects and responses. To understand better
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the cardioprotective mechanisms in PDE3B−/− heart, more studies
will be required to identify specific target protein(s) of PKA and a
possible role for PKG in cAMP/cGMP cross talk, as well as to
define the precise localization and functional role of connexin-43
in ICEFs.
In membrane repair machinery dynamics, TRIM72 is thought
to interact physically with dysferlin and caveolin-3 and to translocate
them to sites of membrane damage (41). Recently it has been
demonstrated that I/R reduces the protein level of TRIM72 and that
preconditioning prevents I/R-induced down-regulation of TRIM72
(56). In addition, I/R-induced mitochondrial dysfunction and car-
diomyocyte death were exacerbated in TRIM72-deficient mice (57).
Therefore, the increased amount of TRIM72 in PDE3B−/− ICEFs
(Fig. 6 and Table S2) is consistent with the idea that the PDE3B−/−
heart is preconditioned. Although the involvement of mitochondria
in TRIM72-mediated cardioprotection is not certain, our findings
suggest that ICEF signalosomes may be a specialized microdomain
that delivers membrane repair machinery to damaged mitochondrial
membranes. The increased amount of TRIM72 in PDE3B−/− ICEFs
and the accumulation of TRIM72 in ICEFs during perfusion in the
presence of the PDE3 inhibitor cilostamide support the notion that
selective inhibition of myocardial PDE3B might provide a novel
cardioprotective therapeutic strategy for the treatment of ischemic
injury and myocardial infarction.
Caveolin-3 is a skeletal, cardiac, and smooth muscle-specific
isoform of caveolin, a protein marker for caveolae. Although
recognized as cholesterol- and sphingolipid-enriched 50- to 100-nm
invaginations of the plasma membrane (18, 39, 58), caveolae also
are found in non-plasma membrane locations (e.g., developing
T-tubules) (59). Although no significant changes in the number
of caveolae and mitochondria were observed between WT and
PDE3B−/− heart, more mitochondria in PDE3B−/− heart were in
contact with T-tubules or T-tubule/SR dyads (Fig. 4 A and B),
whose T-tubule membranes are derived from and are continuous
with caveolae (Fig. 4A). During ischemia, the amount of caveolin-3,
which colocalizes with PDE3B, increases in LM fractions (Fig. 5B)
and is incorporated into ICEFs (Fig. 6B and Fig. S6B). Taken
together, the increased amount of CaV1.2 and calsequestrin in
PDE3B−/− ICEFs (Fig. S8 B–D), the increased number of contacts
between mitochondria and T-tubules or dyads (Fig. 4C), and the
localization of PDE3B on or near T-tubules (Fig. 3 B–E) suggest
mechanisms, perhaps similar to preconditioning, whereby com-
partmentalized cardioprotective signaling molecules in caveolae/
signalosomes translocate to PDE3B−/− mitochondria, resulting in
reduced Ca2+ overload and reduced MPT pore opening (16).
cAMP-signaling pathways are highly compartmentalized, and
PDEs play an important role in this compartmentalization
(1, 19, 21, 48, 49). Individual PDEs are targeted to or tethered
at different subcellular locations where they are incorporated,
via protein/protein interactions, into macromolecular signaling
complexes. In these microdomains they regulate compartment-
restricted cAMP gradients and specific cAMP-signaling path-
ways and, thereby, specific biological processes (19, 21, 48, 49).
Using PDE3A−/− and PDE3B−/−mice, we found that PDE3A, not
PDE3B, regulates basal myocardial contractility (27, 43). PDE3A,
as a component of an SERCA2 multimolecular regulatory com-
plex, modulates myocardial contractility by regulating cAMP-
mediated phosphorylation of phospholamban, activation of
SERCA2, and uptake of Ca2+ into the SR (27). Our recent
findings indicate that human PDE3A is a component of a
similar SERCA2 regulatory complex in human myocardium
(60). In adipocytes, PDE3B also is recruited to localized
multimolecular complexes that regulate insulin and cAMP/PKA-
signaling pathways (61, 62).
In this regard, PI3Kγ is a multifunctional protein, which has
been shown to serve as a link between cAMP/PKA- and phospha-
tidylinositol(3,4,5)-triphosphate (PIP3)-signaling pathways (63–65).
Specifically, in isolated murine ventricular myocytes, PI3Kγ seems
to be an important regulator of PDE4 activity and its function in
modulating cAMP-induced Ca2+ transients, uptake of Ca2+ via
SERCA2 into the sarco/endoplasmic reticulum (SER), and, con-
sequently, enhancing myocardial contractility (50). PI3Kγ also
serves as an A-kinase anchor protein (AKAP)/scaffolding protein
which recruits PDE3A, PDE4A and PDE4B (but not PDE4D),
and PKA to localized multimolecular complexes in isolated murine
ventricular myocytes (51). In these distinct complexes, cAMP/PKA-
induced phosphorylation/activation of these different PDEs initiated
a negative feedback loop which decreased cAMP/PKA-induced
phosphorylation of L-type calcium channels and phospholamban
and thus prevented cAMP-dependent, calcium-induced ventric-
ular arrhythmias (51).
PI3Kγ also recruited PDE3B to a multimolecular complex con-
taining the PI3Kγ p84/p87/p110γ heterodimer, PKA, and PDE3B
(64, 65). In this complex, PKA phosphorylates/activates PDE3B
and phosphorylates PI3Kγ, thus inhibiting its kinase activity and
blocking its proinflammatory effects (64, 65). Through mechanisms
independent of its kinase activity but apparently dependent on its
function as an AKAP/scaffolding protein in the PI3Kγ/PKA/
PDE3B multimolecular complex, PI3Kγ was hypothesized to
protect against cardiac damage produced by pressure overload
induced by transaortic constriction via regulation of PKA-induced
activation of PDE3B and cAMP turnover, maintenance of
β-adrenergic receptor density on the cell surface, and enhancement
of myocardial function and contractility (64, 65, 66). It is possible
that in PDE3B−/− heart the absence of PDE3B in the PI3Kγ/
PKA/PDE3B complex leads to increased cAMP/PKA signaling
(Fig. 2F and Fig. S1B) and increased phosphorylation and in-
hibition of PI3Kγ activity, with decreased production of proin-
flammatory signals. At this point, however, the detailed mechanisms
for the integration of the activated cAMP/PKA-signaling pathways
and the kinase-dependent and -independent actions of PI3Kγ on
the development of the cardioprotective phenotype require further
investigation. Although PI3Kγ regulates multiple PDEs, the mo-
lecular mechanisms for regulation remain largely unknown and
seem to differ in different cells and tissues. This variability is
not surprising, because PDEs in different cells subsume different
roles and associate with different multimolecular complexes.
Taken together, our observations are consistent with a model
in which differentially localized PDE3A and PDE3B enzymes
regulate cAMP compartmentalization and/or Ca2+ transients within
microdomains in the SR that contain PDE3A, SERCA2, and
phospholamban (27) or within microdomains in the sarcomere
that contain PDE3B, CaV1.2, and calsequestrin and are located
where T-tubules, SR, and mitochondria are in close proximity
and, most likely, interact and cross talk (Figs. 3 and 4) (1, 19, 21,
48, 49). PDE3B is relatively highly expressed in tissues important
in the regulation of energy homeostasis (2). Our earlier studies
with adipose tissue from PDE3B−/− mice suggested that PDE3B
regulates energy metabolism (4) and that, in PDE3B−/−mice,
WAT assumed phenotypic characteristics of BAT, including in-
creased mitochondrial biogenesis, oxygen consumption and fatty
acid oxidation, and increased expression of uncoupling protein-1
(47). Given its location (Figs. 3 and 4), PDE3B may be a com-
ponent of MAMs involved in integrating Ca2+ signaling between
mitochondria and SER (23, 24). As in adipose tissue (47), per-
haps PDE3B deletion alters cardiomyocyte energetics and thus
protects the heart from ischemic insult.
We also have suggested that PDE3A, not PDE3B, is the most
likely target of PDE3 inhibitors (e.g., milrinone) that enhance
myocardial contractility (27, 43). However, although the PDE3
inhibitor cilostazol is used for treating intermittent claudication,
a peripheral vascular disease (67), chronic administration of the
PDE3 inhibitor milrinone as therapy for heart failure was asso-
ciated with an increase in the incidence of ventricular arrhythmias
and mortality (68). Yan et al. (33) have suggested that one pos-
sible mechanism for the untoward effects of chronic inhibition of
E2260 | www.pnas.org/cgi/doi/10.1073/pnas.1416230112 Chung et al.
myocardial PDE3, especially PDE3A, by milrinone might involve
phospho-CREB–induced expression of ICER and subsequent
apoptosis and myocardial pathological remodeling. Consistent with
these findings, Oikawa et al. (69) recently have reported that
specific overexpression of myocardial PDE3A1 in transgenic mice
confers protection during I/R by decreasing cAMP signaling and
phosphorylation of CREB, resulting in decreased expression of
ICER and reduced apoptosis during I/R. Taken together, this re-
port and our data suggest that differentially localized PDE3A and
PDE3B modulate I/R injury, perhaps via different but overlapping
mechanisms in distinct compartments (Figs. 3 and 4). We sug-
gest that PDE3B deletion/inhibition confers cardioprotective
effects during I/R, most likely through cAMP/PKA-induced pre-
conditioning, which is associated with the accumulation of proteins
with cardioprotective function in ICEFs, resulting in enhanced
PKA-dependent opening of mitoKCa channels, reduced genera-
tion of ROS, and inhibition of MPT pore opening. In another
compartment, activation/increased expression of PDE3A would
confer protection via inhibition of cAMP signaling, ICER ex-
pression, and apoptosis.
Our current and previously published data (27, 43, 44, 60) and
that of Yan and coworkers (33, 69) also clearly point out the
need for, problems with, and therapeutic promise of inhibitors
that selectively target localized PDE3 isoforms. Currently avail-
able PDE3 inhibitors have little or no selectivity for PDE3A versus
PDE3B, because the catalytic domains of PDE3A and PDE3B are
very similar. In mice with type 2 diabetes, cilostazol enhanced the
ability of exenatide and a dipeptidyl-peptidase-4 inhibitor to limit
the extent of IR injury (70, 71). Given these reports and our
findings of cardioprotection in PDE3B−/− mice, PDE3B-selective
inhibitors might provide benefit in heart transplant patients and
heart failure patients, and perhaps in type 2 diabetics, by limiting I/R
damage. The case for PDE3A inhibitors, which enhance con-
tractility but also may increase apoptosis and pathological remod-
eling in cardiomyocytes, is much more complex. Three isoforms
generated from the single PDE3A gene— PDE3A1, PDE3A2, and
PDE3A3—have been identified (72). These isoforms possess
identical amino acid sequences except for the deletion of dif-
ferent lengths of the N-terminal region, and the recombinant (r)
PDE3A1, rPDE3A2, and rPDE3A3 isoforms exhibit virtually
identical catalytic properties and inhibitor sensitivities (73). Se-
lective inhibition of PDE3A isoforms that are incorporated into
the SERCA2 regulatory complex described above or blocking
the integration of PDE3A into these SERCA2-containing com-
plexes might enhance contractility and provide therapy for heart
failure without the harmful effects of increased apoptosis and
pathological remodeling that might accompany diffuse increases in
intracellular cAMP content in other compartments that arise from
global inhibition of PDE3A isoforms. Although it is tempting to
draw connections and speculate about the role of PDE3A in human
cardiovascular physiology and pathophysiology, it is less justified to
do so regarding PDE3B, because less is known about its location
and function in human heart.
In summary, in this study we isolated, identified, and charac-
terized ICEFs/signalosomes in mouse heart mitochondrial frac-
tions and suggested their importance in physiological regulation of
cardioprotection in PDE3B−/− heart. Importantly, we demon-
strated, for the first time to our knowledge, that ICEFs may be
mitochondria-specific signalosomes that share characteristics of
signalosomes isolated from heart homogenates by conventional
methods (17) and contain cardioprotective proteins, including
connexin-43, several calcium-signaling proteins (Fig. S7), and
membrane repair machinery (40), including recently described
TRIM72 (Fig. 6F) (56, 57). Further study is required to un-
derstand mechanisms for preconditioning in PDE3B−/− heart, how
PKA regulates ICEF assembly, and how cardioprotective signaling
molecules in ICEFs are transferred to mitochondria and activate
mitoKCa channels and other cardioprotective events.
Experimental Procedures
Animals. PDE3A−/− and PDE3B−/− mice were generated as previously de-
scribed (3, 4). Protocols for mouse generation and maintenance and all an-
imal studies were approved by the National Heart, Lung, and Blood Institute
Animal Care and Use Committee (Protocol H-0024).
Statistical Analysis. Data are expressed as mean ± SEM. Student’s t test or
one-way ANOVA were used for comparison of groups. Values of P less than
0.05 were considered statistically significant.
Further details are given in SI Experimental Procedures.
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